Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
- Кому может быть актуально
- Состояния в реестре: Crohn Disease. Базовые параметры: 18 лет — 65 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Китай
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Epidemiological Characteristics and Efficacy Evaluation of Refractory Crohn's Disease: a Multicenter, Prospective and Observational Cohort Study
Обзор
Difficult to treat Crohn's disease (DTT-CD) was defined by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) in 2023, which refers to CD patients with poor response to drug treatment and poor prognosis. Foreign epidemiological studies have shown that DTT-CD accounts for 24.8% of all CD patients, and most of them are patients with advanced treatment failure according to more than two different mechanisms. Our previous retrospective data suggested that compared with foreign DTT-CD patients, there was no significant difference in the proportion of patients with advanced treatment failure due to more than two different mechanisms, but the proportion of patients with recurrence after two intestinal resection and complex anal fistula was increased. Therefore, this project aims to determine the current prevalence and epidemiological status of DTT-CD in China; To clarify the difference in efficacy and prognosis between DTT-CD patients and non DTT-CD patients using advanced treatment (including biological agents and small molecule drugs); Objective to evaluate the incidence and risk factors of non DTT-CD patients progressing to DTT-CD within 1 year. To further verify whether the domestic DTT-CD population is significantly different from the foreign population, and provide theoretical support for the selection of subsequent treatment options.
Первичные конечные точки
- steroid-free remission [Срок оценки: From the beginning of enrollment to 1 year]
Вторичные конечные точки (7)
- Epidemiological status of Difficult-To-Treat Crohn's Disease [Срок оценки: From the beginning of enrollment to three months later]
- Clinical reponse rate [Срок оценки: From the begining of enrollment to 1 year.]
- Clinical remission rate [Срок оценки: From the begining of enrollment to 1 year]
- Endoscopic outcome [Срок оценки: From the begining of enrollment to 1 year]
- Ultrasound outcome [Срок оценки: From the begining of enrollment to 1 year]
- Postoperative recurrence rate [Срок оценки: From the begining of enrollment to 1 year]
- Safety differences [Срок оценки: From the begining of enrollment to 1 year]
Критерии участия
Критерии включения
- The diagnosis of Crohn's disease was confirmed;
- Patients aged 18-65;
- Informed consent was obtained voluntarily.
Критерии исключения
- The diagnosis of CD was unclear;
- The clinical baseline data were missing seriously;
- Patients currently enrolled in clinical trials or receiving experimental drugs;
- Other contraindications to biologics or small molecule drugs (including active infection, pregnancy, etc.);
- Patients with short bowel syndrome;
- Patients with a small bowel or colostomy.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
Китай · 1 центр
- Sixth Affiliated Hospital, Sun Yat-sen University — Гуанчжоу
Идентификаторы
NCT: NCT07364734 · 2025-ZSLYEC-556